Announcements Trials

Browse Landscape Eligibility

Clinical Trials

1 trials

Recent Start date Enrollment

Has results × Peritoneal Neoplasms × talimogene laherparepvec × Clear all

Phase

Status

Sponsor Class

Study Type

Interventional 1

Sponsor

Cancer Type

Conditions

Melanoma 8 Sarcoma 3 Neoplasm Metastasis 3 Triple Negative Breast Neoplasms 2 Breast Neoplasms 2 Squamous Cell Carcinoma of Head and Neck 1 Recurrence 1 Rectal Neoplasms 1 Pleural Effusion, Malignant 1 Peritoneal Neoplasms 1 Pancreatic Neoplasms 1 Lung Neoplasms 1 Inflammatory Breast Neoplasms 1 Head and Neck Neoplasms 1 Colorectal Neoplasms 1 Carcinoma, Squamous Cell 1 Carcinoma, Merkel Cell 1 Carcinoma, Hepatocellular 1 Carcinoma, Ductal, Breast 1 Carcinoma, Ductal 1 Advanced Non CNS Tumors 1 Adenocarcinoma 1

Interventions

Paclitaxel 8 Carboplatin 6 Cisplatin 5 Hyperthermic Intraperitoneal Chemotherapy 4 Cytoreduction Surgical Procedures 3 Bevacizumab 3 nintedanib 2 Mitomycin 2 Gemcitabine 2 Fluorouracil 2 Docetaxel 2 vandetanib 1 talimogene laherparepvec 1 strattice 1 sodium thiosulfate 1 poly(I).poly(c12,U) 1 pembrolizumab 1 olaparib 1 liposomal doxorubicin 1 lentiviral minigene vaccine of COVID-19 coronavirus 1 farletuzumab 1 enzastaurin 1 catumaxomab 1 birinapant 1 atezolizumab 1 alvimopan 1 Trabectedin 1 Topotecan 1 Surgical Procedures, Operative 1 Saline Solution 1

Date Range

30 days 90 days 1 year All

Options

Has results Has announcements

NCT03663712 2024-11-20

TEMPO

Duke University

Phase 1 Completed

28 enrolled 10 charts

Peritoneal Neoplasms

Data powered by HemOnc (CC BY 4.0) Colophon ⚡